Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Medivir, Audiocast, Q2'25

By Inderes8/21/2025, 12:00 PM
Medivir

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jens Lindberg
00:01 - 04:03

Thank you and welcome, everyone, to our Q2 report here at Medivir AB. And we look forward to walking through the progress we've seen in Q2 and addressing key questions as we continue our preparations for the phase two study with Fostrox and Lenvima. If we look back at Q2, or even if we look even further than that, we can observe significant developments. So to start, we presented final data from the now closed phase 1b/2 study with Fostrox plus Lenvima in Q1. Interestingly, as of today or in the past few days, the patient who has been on treatment the longest has now been treated with continued benefit for three years, which is a very, very long time for a second-line liver cancer patient. And we also continue to follow what's happening competitively in the second-line liver cancer space, especially when there are new data presentations at major congresses. In Q2, two of those congresses took place: ASCO in the US and ESMO-GI here in Europe. And we can conclude, as we have concluded many times before, that the combination of Fostrox plus Lenvima does maintain a front-runner position in second line treatments. And we will touch on this, and I will come back to this in a bit more detail. Importantly, patent protection is critical when we develop drugs. And in Q2, we saw another major patent authority, in this case Japan, approve the very important Fostrox plus Lenvima patent, providing protection until 2041. And this particular combination patent is a key element in the Fostrox patent strategy, especially with Japan. Following the EU and also Australia, it is a very good sign and signal, and it makes us look forward to additional patent approvals in other key regions. And thirdly, in Q2, we had a partner, IGM Biosciences, who was acquired by Centra in Q2. One of them being the lack of activity seen with their own DR5 agonist. And this is the molecule they used to combine with Birinapant. And they also combined it with other molecules. As a result, when they were acquired, they returned Birinapant to us. And moving forward, we will, of course, evaluate the best option forward for the molecule. Finally, it goes without saying that in our current clinical and financial situation, the key focus at the moment is to find the best possible solution to finance the next step. And we will come back to this and touch on this at the end as we go through our financial situation. But with that, um, and as I mentioned, in the room apart from myself and Magnus, Pia will then go through some of the data from the recent congresses, and we are joined by our CFO, Fredrik, who is here for the Q&A session as well. So with that, uh, let's start from the top, I will hand over to Pia to take us through the recent events in the liver cancer field and what it means for the Fostrox plus Lenvima combination.

Pia Baumann
04:04 - 11:01

Thank you and welcome, everyone to our Q2 report here at Medivir AB. James. And, uh, as James said, ASCO and ESMO-GI have taken place this spring and summer. In the second-line setting, where we are developing Fostrox and Lenvatinib, the data has been scarce but consistent with what has been shown previously. And it confirms that Fostrox plus Lenvatinib is a promising second-line treatment in advanced HCC. And, um, there is a significant gap in clinical data for second-line advanced HCC. And that is really the reason why there is no consensus on what treatment to use. And the recommendation, as you can see from this ESMO-GI presentation, is still to include these patients in a clinical study. Not all patients will have a clinical study available. And then you use more or less what is available or what has data in first-line or has been used after Sorafenib. Um, and also what is again confirmed is that immune therapy is established in first-line and will remain in this setting with, uh, TECENTRIQ Avastin or, as it will say in all these slides, atezolizumab plus bevacizumab, particularly in first-line, which is used in around 90% of the patients in first-line. You can go to the next slide. So this sounds a little bit crazy actually at a conference that is focusing on liver cancer. But at ESMO-GI, there was only one presentation with prospective clinical data in the second-line HCC setting. And this presentation used Cabozantinib in the second line. And it's not only after I, you can see it to the left here, but it was mainly, uh, TECENTRIQ Avastin atezo that was used in the first line setting. And in this study, there was a median progression-free survival of three months and an overall response rate of. It was only one patient that responded, with a response rate of 4.5%. And this is really in line with what we have seen previously. I can show you some more data if we go to the next slide. And that was from a prospective registry from Europe, a study that looked into 230 patients who had received either Sorafenib or Lenvatinib in the second-line setting, trying to understand what is the outcome in the second-line setting. So, this is more or less what was presented at ESMO-GI. When it comes to the setting where we are developing Fostrox plus Lenvatinib. And if you go to the next slide, there has also been a recent review published in Annals of Hepatology in February this year, where they looked into the data in the second-line setting. And it includes both prospective and retrospective studies here. But all in all, you can say that all of this data confirms what we have seen previously, with an overall response rate of less than 10%, a disease control rate of around 65%, and a median progression-free survival or time to progression of around four months. And this data can be compared to what we have shown in the Phase 1B/2A study with Fostrox plus Lenvatinib, where we saw an overall response rate of 24%, disease control rate of 81%, and a time to progression of 10.9 months, which is substantially better than what has been seen with Lenvatinib, with other TKIs, or with immunotherapy combinations in the same setting in second-line advanced HCC. Uh, and with this limited clinical data in second line, the development in HCC is really focused on first line liver cancer. There is, however, continued support for immune therapy. In the first-line setting. It's solid, and it's further supported by quality of life, an endpoint that has not been so much in focus in oncology development. But recently, ESMO-GI and similar conferences have started to recognize health-related quality of life as a key parameter in determining the clinical value of anti-cancer treatments. And it could also enhance the overall assessment of therapeutic efficacy. And why am I saying this here now? It's because the current treatment algorithm is the one that we are working with. And if you go to the next slide, we can also see a recent publication in support of immune therapy in first-line, where they integrated health-related quality of life in addition to overall survival. The most important endpoint in liver cancer shows that TECENTRIQ Avastin or Bev outperformed all other treatments and provided the best balance between quality of life preservation. Uh, that quality of life didn't deteriorate, uh, along with overall survival in advanced HCC. So, our firm assumption is that TECENTRIQ Avastin will continue to be the preferred first-line treatment option, also in the future. And our planned phase two study post-immunotherapy will reflect the future treatment algorithm. And the results from our study will be relevant for the high unmet need in the second-line setting. And with that, I will leave it back to Jess.

Jens Lindberg
11:02 - 15:01

Uh, that quality of life didn't deteriorate, uh, together with overall survival in advanced HCC. Yeah. I mean, the question is always sort of why do we hone in on the first line treatment. But that is, I mean, when we plan for the next phase, it's important that we also plan for a phase that will remain relevant over time. And this is why it's encouraging and important that the design of the study we have, the phase two study with an immunotherapy using TECENTRIQ and Avastin in the first line and then progression, is the right treatment algorithm today. And that treatment algorithm will remain consistent over time. So it's encouraging from that data set to see that TECENTRIQ Avastin as a first-line treatment will remain cemented. And the other part again, if we look at this slide, this is just a treatment algorithm. At the bottom here is the second line where there are no approved options. This is where we are targeting. So again, we are focused on where the biggest unmet medical need is. There hasn't been anything new come into play. As I alluded to or showed, the data we've seen recently confirms that our frontrunner position with the combination remains intact. And, uh, just to kind of reiterate what we talked about before, a couple of things. One, we know that the second line, HCC space is a very large and growing commercial opportunity. When we get to 2030, we're looking at almost a $3 billion market. And if anything, that is likely to be bigger. Again, looking at what we see in terms of the evolution perspective, we've talked about this before as well, but just to emphasize that liver cancer is likely to grow faster than previously anticipated, driven by the alarming increase in fatty liver disease and the risk of fatty liver disease, patients being diagnosed with liver cancer. So with that, considering the size of the market, the market is only going to grow. And our opportunity and our belief that we can be the first approved treatment option in the second line, then it becomes critical to work and strengthen our IP patent strategy and strengthen the patent family. And that's why the combination patent and approval now in Japan is such a key. And it's especially crucial to emphasize this. It's especially important for a product like Fostrox, which is focused on a particular tumor type. So here, the patent is for the combination with Lenvima, which is the combination we are developing. And it's for use in liver cancer. So it means that this will be the approved use, making it difficult for a generic to challenge the patent or argue that Fostrox is being used for a different tumor type, as it will only be approved for liver cancer. Hence, this type of use patent becomes exceptionally strong for a drug with that specific tumor type focus. So, we are very happy that Japan approved it and are looking forward to approval from other regions as well. So with that, uh, we move into the financials.

Magnus Christensen
15:03 - 16:35

So it means that will be the approved use, meaning that it would be difficult for a generic to come in and challenge the patent and argue that Fostrox is being used in a different tumor type, since it will only be approved in liver cancer. Uh, next slide please. Uh, we can see the financial summary, uh, for the second quarter and year-to-date performance to June, and the resulting cash flow was in line with our forecasts and turnover slightly higher in Q2, primarily driven by royalty income from Sinclair. And I will give you some comments regarding external expenses. As you can see, they are significantly lower than last year, mainly due to reduced clinical costs following the completion of the study in November last year. Although we have some clinical trials in the quarter, we will have some additional wrap-up costs expected in Q3 as well. And we have made some investments in the quarter for the planned phase IIb study, and we estimate a lower cash outflow in the coming months. And we continue to work to reduce the cost base that we have today. And some final comments regarding the cash position. And we have strong support from our largest shareholder, and we utilized the loan facility of 30 million SEK during the quarter. And with that, we have a cash balance at the end of June amounting to 38 million. And the estimated cash runway is now until the end of quarter four. Under the current plan and the current assumptions that we have today. Then I will hand back to Jens for some final comments.

Jens Lindberg
16:35 - 17:41

Thank you, Magnus. And just to touch on this, I mean, in our current situation, our number one focus is, of course, to conclude on the best way forward financially for Fostrox. And as soon as we have final clarity on that, we will, of course, communicate. What I can say is that we are in active discussions with different parties to find the best way forward. And before having concluded those discussions, we are very much grateful for the support and belief shown by our main owner, Link, in providing the loan facility, as that enables us to follow through on those discussions. It is difficult to say more at this stage than to reiterate that this is our key priority at the moment, and we will, of course, communicate as soon as we have concluded on those discussions. So with that, we'll stop there and then open up the line for questions.

Operator
17:44 - 18:30

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Joe Pantaenus from H.C. Wainwright. Please go ahead. The next question comes from Richard Romanus from Redeye. Please go ahead.

Josh (representing Joe Pantaenus)
18:31 - 18:43

Hi, this is Josh on for Joe. I had a question about Birinapant. So now that you've regained all the rights to it, is there any additional insight you can provide on how you think about moving it forward?

Magnus Christensen
18:44 - 18:46

Well, I mean, Birinapant.

Unknown 1
18:46 - 19:01

It is an interesting molecule. It has a great safety profile. It does what it's supposed to do mechanistically in cancer cells. And we're currently evaluating several different approaches.

Richard Romanus
19:01 - 19:07

Um, um, I think. Did you answer the previous question?

Unknown 1
19:08 - 19:12

Um, yes. That's correct.

Jens Lindberg
19:14 - 19:14

Are we?

Unknown 1
19:15 - 19:18

I think there's some time delay issue here.

Jens Lindberg
19:18 - 19:27

I'm not sure if we have technical challenges here. We've heard one question so far from Josh at H.C. Wainwright regarding Birinapant.

Unknown 1
19:30 - 19:54

And we can just conclude that with the observation that we're currently working to find a path forward for Birinapant. And we think it's still a very interesting opportunity, both in terms of the many different combinations out there that are potentially useful and the various indications available.

Richard Romanus
19:54 - 19:57

So it's my turn to ask a question because.

Unknown 1
20:02 - 20:04

So that's where we are currently.

Jens Lindberg
20:05 - 20:15

Again, from a technical viewpoint. Not sure if we are being heard or not.

Unknown 2
20:16 - 20:17

Yes, you are.

Jens Lindberg
20:17 - 20:27

Please go ahead. Good, good. So with that, hopefully that answers the Birinapant question. And it sounded like the next person in line was Richard from Redeye.

Unknown 2
20:30 - 20:49

Please go ahead, Richard. We seem to have a problem with Richard's line.

Jens Lindberg
20:52 - 20:55

We did hear Richard a couple of times before.

Richard Romanus
20:55 - 20:57

Yes. Can you hear me?

Jens Lindberg
20:57 - 20:58

We can hear you now, Richard. Yes.

Richard Romanus
20:58 - 20:59

Yeah. Can you hear me?

Unknown 2
20:59 - 21:00

Yes.

Jens Lindberg
21:02 - 21:03

We can hear you.

Richard Romanus
21:03 - 21:13

Okay, I'll just ask the question. Your other external expenses increased slightly from Q1. What?

Magnus Christensen
21:17 - 21:29

We seem to have a problem with Richard's line. I could hear your question, Richard. Yes. And the main reason behind that was the investment we made in CMC. And that's an investment for the planned phase two B. So that's the main reason for that.

Richard Romanus
21:39 - 21:51

Yeah. Can you say something about the funding and dealer environment in oncology? It's been a bit tough up until now. Do you see it changing going forward?

Jens Lindberg
21:54 - 22:52

I think the obvious answer would be yes. I think that it will change. I mean, it's been a difficult sort of situation for a couple of years, I think. Interesting. When we look externally, I mean, we've seen some encouraging news, arguably sort of as of late. So I think inevitably it will sort of swing back. I think from our position, we have been in discussions regarding finding the best way forward. So I think that, um, we, I mean, we look to conclude those discussions, and that's the key focus from our end. And that's not dependent on a shift in the environment, etc. . We just want to make sure we conclude those discussions. And then clearly, considering our financial situation and those discussions, we want to bring them to a close as soon as we possibly can. Of course.

Richard Romanus
22:55 - 22:57

Yes, certainly. Thanks for answering my questions.

Jens Lindberg
23:02 - 23:03

And I think the only thing.

Operator
23:03 - 23:08

The next question comes from Klaus Pallin from DNB Carnegie. Please go ahead.

Unknown 3
23:09 - 23:09

Go ahead.

Klaus Pallin
23:11 - 23:16

So I think that, um, we, I mean, we look to conclude those discussions and that's the key focus from our end. Hello there. Um, thanks for taking my question. If you can hear me.

Jens Lindberg
23:16 - 23:17

We can hear you.

Klaus Pallin
23:17 - 23:28

Um, perfect. Uh, my question relates to the financing. Then, um, I think, uh. Hello?

Jens Lindberg
23:29 - 23:30

We can hear you. Go ahead.

Klaus Pallin
23:30 - 23:50

Magnus indicated that. So I think that, um, we, I mean, we look to conclude those discussions and that's the key focus from our end. Magnus indicated that your costs would perhaps come down somewhat in the coming quarters. And just wondering if that's related to your pausing some initiatives in the preparations for the phase two study, or is it just how it should be?

Magnus Christensen
23:51 - 24:17

No, it's mainly related to the fact that we have some. Even though we completed the study in November last year, we still have some clinical tasks, according to our agreement with our CRO. Um, but the preparations are going according to the plan for the planned phase to be.

Klaus Pallin
24:20 - 24:36

Okay. So if you would, uh, be able to secure funding in the coming months, uh, would it be possible to initiate the phase two study before year-end, or when do you think it would be possible?

Pia Baumann
24:37 - 24:50

So I can respond to that. So, uh, all the preparations, as Magnus has already said, uh, are ongoing. And when we sort of have all the financials in place, we are ready to just press the button and start the study.

Jens Lindberg
24:53 - 25:03

It's always difficult to give a specific timeline. But people are eager, and we're being pushed at every Congress. Let's start as soon as you can. That's, I think, the short answer.

Pia Baumann
25:03 - 25:23

Yeah. And as I mentioned earlier, there is such a high unmet need and there are currently no studies ongoing, more or less. Uh, so, um, we yeah, it's really anticipated that we start this study as quickly as possible as soon as we have the financial part ready.

Unknown 4
25:24 - 25:26

Yes, sure.

Klaus Pallin
25:26 - 25:39

I'm just looking to understand if you are starting to lose some time now as we await a more, uh, proper financing.

Unknown 4
25:41 - 25:41

Yeah.

Pia Baumann
25:43 - 25:44

The timing is crucial, yeah.

Jens Lindberg
25:45 - 26:18

We want to be very clear: the sooner we secure the financing, the better. I mean, from a timing perspective, and this is one of the reasons why we wanted to spend a bit of time on. Are we losing momentum? Are we losing our place in the queue? Are we seeing anyone moving ahead of us, and is there anything we're not seeing clearly? That doesn't mean we want to delay things, but it's reassuring to see that we're not falling behind. But of course, let's secure the financing to be able to start as soon as we possibly can.

Klaus Pallin
26:22 - 26:27

Perfect. Sounds very good, and good luck with that. And thank you for taking my question.

Jens Lindberg
26:30 - 26:31

Thank you.

Operator
26:31 - 26:52

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Jens Lindberg
26:54 - 28:40

Thank you. Uh, and then I mean, just to sort of go back to our overview slide, which we've talked about a few elements today. Uh, we continue to be at the forefront, being the first and only liver-targeted agent. We've shown, quite frankly, with the data we presented in Q1, an encouraging dataset with 10.9 months time to progression. Pia Baumann presented today, once again, additional studies confirming that this is significantly different, and it is clearly longer than what we've seen in other studies in the second-line treatment. And there's nothing else improved. So the window towards becoming the first approved treatment option in the second line is there, and the market is significant. And clearly, again, just to come back to it, just to sort of make that point, uh, our number one focus, apart from making sure that we progress all the preparations for the study, is evidenced by the CMC investments we're doing to ensure that we are prepared. Our number one focus is to conclude on the financial solution to find the best way forward. And to conclude the active discussions that are ongoing. Um, and as soon as we have clarity and as soon as we have landed on that best way forward, then we will communicate as soon as we can. So with that, uh, thank you everyone for dialing in and, uh, have a good rest of the day.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…